The watchdog declined immediate comment
MOSCOW (AFP) – Early clinical trials of a second Russian coronavirus vaccine have proved successful, its developer said on Thursday (Oct 1) after Russia boasted of approving the world’s first vaccine.
Russia‘s Vektor – a top-secret state virology research centre in Siberia – said that early-stage trials were successful for its own experimental vaccine, named EpiVacCorona.
“The first two phases of clinical trials demonstrated the effectiveness and safety of the EpiVacCorona vaccine,” Vektor‘s press department told the Interfax news agency.
Russia announced in August that it had developed the world’s first registered vaccine – named “Sputnik V” after the world’s first satellite.
It raised concerns among Western scientists by announcing that the vaccine – developed by Moscow’s Gamaleya research centre – had received approval before full clinical trials have been completed.
Vektor said it would be possible to make the final conclusions about the efficacy of its vaccine, based on peptides that trigger an immune response, after post-approval clinical trials have been completed.
Russian Health Minister Mikhail Murashko told President Vladimir Putin this week that Vektor‘s vaccine could be approved by the ministry in three weeks.
Vektor said post-registration clinical trials would begin on 5,000 volunteers in Siberia.
The lab said there would be a separate clinical trial involving 150 volunteers who are over 60 years of age.
After that Vektor will begin placebo-controlled trials on 5,000 Russian volunteers between the ages of 18 and 60.
The EpiVacCorona vaccine is a two-component vaccine, and the interval between the administration of the first and second components is 21 days.
Related Story Russia‘s ‘Sputnik V’ Covid-19 vaccine to be tested on 40,000 people Related Story Russian scientist behind Covid-19 vaccine defends ‘wartime’ roll-out Related Story Covid-19 vaccine front runners will soon see their moment of truth Russia plans to manufacture an initial 10,000 doses, Vektor said, with production expected to begin in November.
Vektor declined to comment when contacted by AFP and referred all queries to Rospotrebnadzor, the country’s consumer safety watchdog.
The watchdog declined immediate comment.
The Vektor laboratory complex conducted secret biological weapons research in the Soviet era and stockpiles viruses ranging from Ebola to smallpox. It is located outside the Siberian city of Novosibirsk.
Related Stories: Related Story Interactive: How the world lost one million lives to Covid-19 Related Story MOH removes 2 Covid-19 community cases after further tests Related Story Europe on the verge of a second Covid-19 wave: A hotchpotch of situations and measures Related Story ‘Lockdown Lite’ is the new strategy for fighting Covid-19 Related Story Victoria’s premier doesn’t know who made quarantine decision that led to Australian state’s lockdown Related Story Some feel burned out as the Covid-19 outbreak drags on with no end in sight Related Story New Covid-19 swab test robot offers safe, more comfortable procedure for patients Related Story Malaysia’s Covid-19 reproduction number highest in South-east Asian region on Sept 15, according to UK model Related Story No need to ban imports from companies whose frozen food products have been contaminated by Covid-19: Experts Sign up for our daily updates here and get the latest news delivered to your inbox.
Get The Straits Times app and receive breaking news alerts and more. Download from the Apple App Store or Google Play Store now.